Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study
Abstract Introduction Immune check-point inhibitors (ICI) were a major breakthrough in cancer care, but optimal patient selection remains elusive in most tumors. Methods Overall 173 adult patients with metastatic solid tumors candidates to ICI in clinical trials at our Institution were prospectively...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-02-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-024-03933-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571655956725760 |
|---|---|
| author | Javier García-Corbacho Alberto Indacochea Iván Victoria Débora Moreno Laura Angelats Azucena E. González Navarro Laura Mezquita Fara Brasó-Maristany Patricia Galván Begoña Mellado Nuria Viñolas Tamara Sauri Miquel Nogué Barbara Adamo Joan Maurel Estela Pineda Lydia Gaba Oscar Reig Neus Basté Esther Sanfeliu Manel Juan Aleix Prat Francesco Schettini |
| author_facet | Javier García-Corbacho Alberto Indacochea Iván Victoria Débora Moreno Laura Angelats Azucena E. González Navarro Laura Mezquita Fara Brasó-Maristany Patricia Galván Begoña Mellado Nuria Viñolas Tamara Sauri Miquel Nogué Barbara Adamo Joan Maurel Estela Pineda Lydia Gaba Oscar Reig Neus Basté Esther Sanfeliu Manel Juan Aleix Prat Francesco Schettini |
| author_sort | Javier García-Corbacho |
| collection | DOAJ |
| description | Abstract Introduction Immune check-point inhibitors (ICI) were a major breakthrough in cancer care, but optimal patient selection remains elusive in most tumors. Methods Overall 173 adult patients with metastatic solid tumors candidates to ICI in clinical trials at our Institution were prospectively recruited. Blood samples were collected at cycle 1 (C1D1) and 2 (C2D1) and until the occurrence of progressive disease (PD). C1D1 LIPI, RMH, PMHI, NLR, dNLR, PIPO and GRIm prognostic scores were calculated. The primary endpoint was identifying the best score to predict rapid PD (≤ 4 months) with ICI using logistic regressions accounting for tumor type, and receiving operators characteristics (ROC) with area under curve (AUC), accompanied by an extensive comparison of the score performances in the prediction of overall survival (OS), progression-free survival (PFS), overall response rates (ORR) and durable clinical benefit (DCB). Secondary objectives included describing study cohort outcomes and studying the association between the selected score at C1D1, C2D1 and its dynamics with OS and PFS. Results C1D1 LIPI was the best predictor of rapid PD, OS and PFS, regardless of cancer type, compared to other scores. No score was associated to ORR and only RMH to DCB. Baseline LIPI detected three categories of patients with significantly different OS (p < 0.001) and PFS (p = 0.013). The same was observed at C2D1 for OS and PFS (both p = 0.020). Significant LIPI class shifts were observed in the overall population (p < 0.001), rapid progressors (p = 0.029) and non-rapid progressors (p = 0.009). Retaining a good LIPI or experiencing a shift towards a better prognostic class was associated to improved OS (p = 0.009) and PFS (p = 0.006). C2D1 LIPI, but not C1D1, remained significantly associated to rapid PD in multivariable analysis. Conclusions LIPI may improve patient selection for ICI and guide treatment adjustments according to on-treatment dynamics in a pancancer context. |
| format | Article |
| id | doaj-art-5afd366c60284440bebb0ea740ce5816 |
| institution | Kabale University |
| issn | 1432-0851 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Springer |
| record_format | Article |
| series | Cancer Immunology, Immunotherapy |
| spelling | doaj-art-5afd366c60284440bebb0ea740ce58162025-02-02T12:26:19ZengSpringerCancer Immunology, Immunotherapy1432-08512025-02-0174311510.1007/s00262-024-03933-wBlood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal studyJavier García-Corbacho0Alberto Indacochea1Iván Victoria2Débora Moreno3Laura Angelats4Azucena E. González Navarro5Laura Mezquita6Fara Brasó-Maristany7Patricia Galván8Begoña Mellado9Nuria Viñolas10Tamara Sauri11Miquel Nogué12Barbara Adamo13Joan Maurel14Estela Pineda15Lydia Gaba16Oscar Reig17Neus Basté18Esther Sanfeliu19Manel Juan20Aleix Prat21Francesco Schettini22The Clinical Trials Unit of Medical Oncology Department, Virgen de la Victoria University Hospital/IBIMAMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaImmunology Service, Hospital Clinic of Barcelona, Clinic Foundation for Biomedical Research - August Pi I Sunyer Biomedical Research Institute (FCRB-IDIBAPS)Medical Oncology Department, Hospital Clinic of BarcelonaTranslational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)Medical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital General of GranollersMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaMedical Oncology Department, Hospital Clinic of BarcelonaTranslational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)Immunology Service, Hospital Clinic of Barcelona, Clinic Foundation for Biomedical Research - August Pi I Sunyer Biomedical Research Institute (FCRB-IDIBAPS)Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS)Medical Oncology Department, Hospital Clinic of BarcelonaAbstract Introduction Immune check-point inhibitors (ICI) were a major breakthrough in cancer care, but optimal patient selection remains elusive in most tumors. Methods Overall 173 adult patients with metastatic solid tumors candidates to ICI in clinical trials at our Institution were prospectively recruited. Blood samples were collected at cycle 1 (C1D1) and 2 (C2D1) and until the occurrence of progressive disease (PD). C1D1 LIPI, RMH, PMHI, NLR, dNLR, PIPO and GRIm prognostic scores were calculated. The primary endpoint was identifying the best score to predict rapid PD (≤ 4 months) with ICI using logistic regressions accounting for tumor type, and receiving operators characteristics (ROC) with area under curve (AUC), accompanied by an extensive comparison of the score performances in the prediction of overall survival (OS), progression-free survival (PFS), overall response rates (ORR) and durable clinical benefit (DCB). Secondary objectives included describing study cohort outcomes and studying the association between the selected score at C1D1, C2D1 and its dynamics with OS and PFS. Results C1D1 LIPI was the best predictor of rapid PD, OS and PFS, regardless of cancer type, compared to other scores. No score was associated to ORR and only RMH to DCB. Baseline LIPI detected three categories of patients with significantly different OS (p < 0.001) and PFS (p = 0.013). The same was observed at C2D1 for OS and PFS (both p = 0.020). Significant LIPI class shifts were observed in the overall population (p < 0.001), rapid progressors (p = 0.029) and non-rapid progressors (p = 0.009). Retaining a good LIPI or experiencing a shift towards a better prognostic class was associated to improved OS (p = 0.009) and PFS (p = 0.006). C2D1 LIPI, but not C1D1, remained significantly associated to rapid PD in multivariable analysis. Conclusions LIPI may improve patient selection for ICI and guide treatment adjustments according to on-treatment dynamics in a pancancer context.https://doi.org/10.1007/s00262-024-03933-wLIPI scoreImmune check-point inhibitorsImmunotherapyMetastaticCancer |
| spellingShingle | Javier García-Corbacho Alberto Indacochea Iván Victoria Débora Moreno Laura Angelats Azucena E. González Navarro Laura Mezquita Fara Brasó-Maristany Patricia Galván Begoña Mellado Nuria Viñolas Tamara Sauri Miquel Nogué Barbara Adamo Joan Maurel Estela Pineda Lydia Gaba Oscar Reig Neus Basté Esther Sanfeliu Manel Juan Aleix Prat Francesco Schettini Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study Cancer Immunology, Immunotherapy LIPI score Immune check-point inhibitors Immunotherapy Metastatic Cancer |
| title | Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study |
| title_full | Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study |
| title_fullStr | Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study |
| title_full_unstemmed | Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study |
| title_short | Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study |
| title_sort | blood based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check point inhibition a prospective longitudinal study |
| topic | LIPI score Immune check-point inhibitors Immunotherapy Metastatic Cancer |
| url | https://doi.org/10.1007/s00262-024-03933-w |
| work_keys_str_mv | AT javiergarciacorbacho bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT albertoindacochea bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT ivanvictoria bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT deboramoreno bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT lauraangelats bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT azucenaegonzaleznavarro bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT lauramezquita bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT farabrasomaristany bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT patriciagalvan bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT begonamellado bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT nuriavinolas bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT tamarasauri bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT miquelnogue bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT barbaraadamo bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT joanmaurel bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT estelapineda bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT lydiagaba bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT oscarreig bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT neusbaste bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT esthersanfeliu bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT maneljuan bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT aleixprat bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy AT francescoschettini bloodbasedprognosticscoresandearlydynamicsunderimmunotherapytoselectpatientswithmetastaticsolidtumorsforcontinuingimmunecheckpointinhibitionaprospectivelongitudinalstudy |